Evidence map›Paper›PMID 36359218›Full record

ReviewBiomedicines2022

Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation.

Predrag Sikiric, Mario Udovicic, Ivan Barisic, Diana Balenovic, Gordana Zivanovic Posilovic, Dean Strinic, Sandra Uzun, Suncana Sikiric, Ivan Krezic, Helena Zizek and 15 more

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 1 institution in 1 country.

Predrag SikiricDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Mario UdovicicDepartment of Internal Medicine, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Ivan BarisicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Diana BalenovicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Gordana Zivanovic PosilovicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Dean StrinicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Sandra UzunDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0002-2346-3740
Suncana SikiricDepartment of Pathology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Ivan KrezicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Helena ZizekDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Haidi YagoDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Slaven GojkovicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0003-4020-326X
Ivan Maria SmodayDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Luka KalogjeraDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0002-1703-0033
Hrvoje VranesDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0003-3544-8385
Marija SolaDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Sanja StrbeDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Antun KoprivanacDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0003-2758-8396
Ivica Premuzic MestrovicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Tomislav MestrovicDepartment of Surgery, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Predrag PavicDepartment of Surgery, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Anita SkrticDepartment of Pathology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0002-9275-7283
Alenka Boban BlagaicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Martina Lovric BencicDepartment of Internal Medicine, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Sven SeiwerthDepartment of Pathology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
University of Zagreb · HR

Funding

University of Zagreb 099
6 · The paper itself

Abstract

In heart disturbances, stable gastric pentadecapeptide BPC 157 especial therapy effects combine the therapy of myocardial infarction, heart failure, pulmonary hypertension arrhythmias, and thrombosis prevention and reversal. The shared therapy effect occurred as part of its even larger cytoprotection (cardioprotection) therapy effect (direct epithelial cell protection; direct endothelium cell protection) that BPC 157 exerts as a novel cytoprotection mediator, which is native and stable in human gastric juice, as well as easily applicable. Accordingly, there is interaction with many molecular pathways, combining maintained endothelium function and maintained thrombocytes function, which counteracted thrombocytopenia in rats that underwent major vessel occlusion and deep vein thrombosis and counteracted thrombosis in all vascular studies; the coagulation pathways were not affected. These appeared as having modulatory effects on NO-system (NO-release, NOS-inhibition, NO-over-stimulation all affected), controlling vasomotor tone and the activation of the Src-Caveolin-1-eNOS pathway and modulatory effects on the prostaglandins system (BPC 157 counteracted NSAIDs toxicity, counteracted bleeding, thrombocytopenia, and in particular, leaky gut syndrome). As an essential novelty noted in the vascular studies, there was the activation of the collateral pathways. This might be the upgrading of the minor vessel to take over the function of the disabled major vessel, competing with and counteracting the Virchow triad circumstances devastatingly present, making possible the recruitment of collateral blood vessels, compensating vessel occlusion and reestablishing the blood flow or bypassing the occluded or ruptured vessel. As a part of the counteraction of the severe vessel and multiorgan failure syndrome, counteracted were the brain, lung, liver, kidney, gastrointestinal lesions, and in particular, the counteraction of the heart arrhythmias and infarction.

Indexed as

arrhythmiascongestive heart failurehearth disturbancesmyocardial infarctionpeptide therapypulmonary hypertensionstable gastric pentadecapeptide BPC 157thrombosis

Identifiers

PMID36359218
PMCPMC9687817
OpenAlexW4307238659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.